24 November 2021
Selvita Group reports a dynamic increase in revenues for Q3 2021 YTD
22 September 2021
Selvita Group reports over 109% increase in revenues for H1 2021
21 September 2021
Selvita has received a grant to establish a technological platform, which will enable creation of new generation of drugs against diseases caused by coronaviruses
06 September 2021
Webinar: Screening in drug discovery best practices: past, present, and future
06 September 2021
Selvita will develop a platform to produce focused libraries of bioactive compounds with the use of machine learning and AI methods
19 July 2021
Selvita appoints Dean Bornilla as Vice President of Sales, Head of North America
12 July 2021
Selvita scales its operations with the construction of new research space
02 June 2021
Ardigen webinar – “AI methods in small molecule design.”
26 May 2021
Selvita Group reports over a two-fold increase in revenues for Q1 2021
24 May 2021
Fidelta Webinar – “Immunopathology and preclinical modelling of systemic lupus erythematosus (SLE)”
07 May 2021
Fidelta's Capabilities In Antiviral Drug Discovery
08 April 2021
Selvita Webinar – “Analytical outlook for biosimilar development”
30 March 2021
Breakthrough year in the development of Selvita – strategic acquisition & strong financial results
17 March 2021
Selvita will participate in the upcoming BIO-Europe Spring 2021
16 March 2021
Selvita named the Stock Exchange Company of the Year
04 March 2021
Selvita enters the mWIG40 index
24 February 2021
Selvita to present at the Precision In Drug Discovery & Preclinical Virtual Summit (West Coast)
09 February 2021
Selvita develops the cell-based phenotypic assay platform for drug discovery
20 January 2021
Webinar with live Q&A on modern small molecule drug discovery
04 January 2021
Selvita completes acquisition of Fidelta from Galapagos